<DOC>
	<DOCNO>NCT02838810</DOCNO>
	<brief_summary>As HBsAg clearance uncommon chronic hepatitis B ( CHB ) patient nucleoside analogue ( NAs ) therapy . The purpose study optimize HBsAg clearance CHB Patients sequential treatment pegylated interferon alpha NAs .</brief_summary>
	<brief_title>The Optimizing Treatment PegIFN Alfa HBeAg-negative CHB Patients With Low Level HBsAg</brief_title>
	<detailed_description>In order optimize HBsAg clearance CHB patient low level HBsAg , investigator enrol patient receive , respond , NAs 12 month ( see inclusion criterion ) , patient switch receive peginterferon alfa-2a 180 micrograms/week peginterferon alfa-2b 80 micrograms/week . The long course treatment 96 week . After treatment , patient follow 24 week . During 96 week course treatment , HBsAg level monitor . When HBsAg level le 0.05 IU/mL , peginterferon treatment stop patient receive 24 week follow .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . CHB patient receive single NAs 12 month . 2 . Hepatitis B e antigen ( HBeAg ) negative . 3 . Hepatitis B surface antigen ( HBsAg ) positive &lt; 1000 IU/mL . 4 . Hepatitis B virus DNA &lt; 100 IU/mL . 1 . Patients liver cirrhosis , Hepatocellular Carcinoma AFP &gt; 2 ULN malignancy . 2 . Patients factor cause liver disease . 3 . Pregnant lactating woman . 4 . Patients concomitant HIV infection congenital immune deficiency disease . 5 . Patients diabetes , autoimmune disease . 6 . Patients important organ dysfunction . 7 . Patients serious complication ( e.g. , infection , hepatic encephalopathy , hepatorenal syndrome , gastrointestinal bleeding . ) 8 . Patients receive antineoplastic immunomodulatory therapy past 12 month . 9 . Patients previous use IFN anti hepatitis B virus treatment NAs drug resistance . 10 . Patients ca n't come back clinic followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>peginterferon alfa</keyword>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>